Research programme: CNS therapeutics - Jagiellonian University/Neurolixis
Latest Information Update: 28 Feb 2019
Price :
$50 *
At a glance
- Originator Jagiellonian University; Neurolixis
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder; Schizophrenia
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Major depressive disorder in Poland
- 28 Feb 2019 No recent reports of development identified for research development in Major depressive disorder in USA
- 28 Feb 2019 No recent reports of development identified for research development in Schizophrenia in Poland